CN106928122A - 3‑烷氧基季碳氧化吲哚及其制备方法 - Google Patents

3‑烷氧基季碳氧化吲哚及其制备方法 Download PDF

Info

Publication number
CN106928122A
CN106928122A CN201710131094.XA CN201710131094A CN106928122A CN 106928122 A CN106928122 A CN 106928122A CN 201710131094 A CN201710131094 A CN 201710131094A CN 106928122 A CN106928122 A CN 106928122A
Authority
CN
China
Prior art keywords
nmr
quaternary carbon
cdcl
compound
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710131094.XA
Other languages
English (en)
Inventor
刘雄利
陈智勇
刘欢欢
周英
俸婷婷
杨楷模
林冰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou University
Sichuan University of Science and Engineering
Original Assignee
Guizhou University
Sichuan University of Science and Engineering
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou University, Sichuan University of Science and Engineering filed Critical Guizhou University
Priority to CN201710131094.XA priority Critical patent/CN106928122A/zh
Publication of CN106928122A publication Critical patent/CN106928122A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一种3‑烷氧基季碳氧化吲哚，本发明通过将3‑氯季碳氧化吲哚在醇类溶剂中,加入无机碱或者有机碱,进行3‑烷氧基化反应，获得3‑烷氧基季碳氧化吲哚，该类骨架包含在许多医药候选药物分子中，例如药物活性分子CPC‑1就包含该类骨架；3‑烷氧基季碳氧化吲哚的合成也是潜在的药物分子中间体或和药物类似物，具有极其重要的研究意义。本发明操作简单易行，原料合成便宜易得，直接在醇类溶剂中进行反应，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。

Description

3-烷氧基季碳氧化吲哚及其制备方法
技术领域
本发明涉及化学技术领域，尤其是一种3-烷氧基季碳氧化吲哚及其制备方法。
背景技术
3-羟基季碳氧化吲哚骨架广泛存在于许多具有重要生物活性的吲哚生物碱或药物分子中，例如天然产物分子和药物活性分子maremycin，convolutamydine，donaxaridine,CPC-1以及SM-130686包含3-羟基季碳氧化吲哚骨架，具有显著的生物活性(如图7所示)。在这个背景下，鉴于含3-羟基季碳氧化吲哚骨架天然产物具有潜在的生物活性，因此，合成一系列具有3-烷氧基季碳氧化吲哚化合物可能会产生一系列结构和活性上有意义的新化合物分子，它们的合成可以为生物活性筛选提供化合物源，对寻找新型的先导化合物具有重要的意义。
发明内容
本发明的目的是：提供一种3-烷氧基季碳氧化吲哚及其制备方法，它是一类重要的医药中间体和药物类似物，对药物筛选和制药行业具有重要的应用价值，且其合成方法非常经济简便。
本发明是这样实现的：3-烷氧基季碳氧化吲哚，该化合物具有如下通式(I)的结构：
式中，R1为苯环上不同取代的苄基；R2为氢或卤素；R3为烷基。
3-烷氧基季碳氧化吲哚的制备方法，将3-氯季碳氧化吲哚在醇类溶剂中,加入无机碱或者有机碱,进行3-烷氧基化反应，获得3-烷氧基季碳氧化吲哚。
所述的无机碱包括碳酸钠、碳酸钾、碳酸氢钠、碳酸氢钾、磷酸钾或磷酸氢钾。
所述的有机碱为DBU、DMAP、Et3N或金鸡纳碱。
所述的碱性催化剂的加入量为3-氯季碳氧化吲哚摩尔量的1-100％。
所述的醇类溶剂为甲醇、乙醇、丙醇、异丙醇、正丁醇或苄醇。
3-氯季碳氧化吲哚在醇类溶剂中反应温度为25至100℃，反应时间为3-10小时。
本发明的反应原理如下：
其中，R1，R2，R3如上所述。Cat.为碱性催化剂。
通过采用上述技术方案，以相应的3-氯季碳氧化吲哚在醇类溶剂中,加入无机碱或者有机碱,进行3-烷氧基化反应，获得3-烷氧基季碳氧化吲哚。它是一类重要的医药中间体和药物类似物，对药物筛选和制药行业具有重要的应用价值，本发明操作简单易行，原料合成便宜易得，可以在各种有机溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。
附图说明
附图1-6为本发明的实施例化合物3aa-3ca的核磁共振谱图；
附图7为本发明的技术背景说明图；
附图8为本发明的化合物的单晶图。
具体实施方式
本发明的实施例1：
3-烷氧基季碳氧化吲哚3aa的制备，在圆底烧瓶中，依次加入3-氯季碳氧化吲哚1a(0.4mmol)，4.0mL甲醇2a，20mol％Na2CO3(8.5mg,0.08mmol)，充分搅拌，室温反应8小时。减压蒸馏除掉溶剂，残留油状物硅胶柱层析(300-400目)分离(石油醚：乙酸乙酯＝3：1)，得到淡黄色固体3aa，熔点：120.3-122.5℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.08(s,3H),3.11(d,J＝12.8Hz,1H),3.32(d,J＝12.8Hz,1H),6.80-6.83(m,1H),6.93-6.96(m,2H),7.02-7.11(m,5H),7.22-7.26(m,1H),9.13(br s,1H)；13CNMR(CDCl3,100MHz)δ:43.6,5.3.3,84.2,110.4,122.6,125.3,126.3,126.7,127.6,129.8,130.6,133.9,141.2,178.6；HRMS(ESI-TOF)m/z:Calcd.for C16H15NNaO2[M+Na]+:276.1000；Found:276.1004。
化合物3ba～3jf的制备方法同化合物3aa，投料比与化合物3aa相同，可得到化合物3ba～3jf，反应产率见表1至表3，但需强调的是本发明的化合物不限于表1至表3所表示的内容。
表1：3-烷氧基季碳氧化吲哚的化学结构
表2：3-烷氧基季碳氧化吲哚的化学结构
表:3：3-烷氧基季碳氧化吲哚的化学结构
本实施例制备化合物3ba：淡黄色固体，熔点：142.3-144.1℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.03(d,J＝12.8Hz,1H),3.05(s,3H),3.23(d,J＝12.8Hz,1H),3.66(s,3H),6.57-6.61(m,2H),6.79-6.85(m,3H),7.01-7.03(m,2H),7.20-7.25(m,1H),8.98(br s,1H)；13C NMR(CDCl3,100MHz)δ:42.9,53.4,55.1,84.4,110.5,113.1,122.7,125.4,126.0,126.6,129.9,131.7,141.4,158.5,178.8；HRMS(ESI-TOF)m/z:Calcd.for C17H17NNaO3[M+Na]+:306.1106；Found:306.1107.
本实施例制备化合物3ca：淡黄色固体，熔点：130.7-134.2℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:2.13(s,3H),2.97-3.01(m,4H),3.19(d,J＝12.8Hz,1H),6.72-6.81(m,5H),6.94-6.99(m,2H),7.13-7.18(m,1H),8.94(br s,1H)；13CNMR(CDCl3,100MHz)δ:21.0,43.2,53.2,84.2,110.4,122.5,125.3,126.5,128.3,129.7,130.4,130.7,136.2,141.2,178.7；HRMS(ESI-TOF)m/z:Calcd.for C17H17NNaO2[M+Na]+:290.1157；Found:290.1154.
本实施例制备化合物3da：淡黄色固体，熔点：120.3-122.4℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.05(d,J＝13.2Hz,1H),3.08(s,3H),3.26(d,J＝13.2Hz,1H),6.81-6.84(m,3H),7.03-7.06(m,2H),7.20-7.26(m,3H),8.82(br s,1H)；13C NMR(CDCl3,100MHz)δ:43.0,53.3,83.8,110.5,121.0,122.7,125.2,126.0,130.0,130.8,132.3,132.9,141.0,178.2；HRMS(ESI-TOF)m/z:Calcd.for C16H14BrNNaO2[M+Na]+:354.0106；Found:354.0106.
本实施例制备化合物3ea：淡黄色固体，熔点：184.5-187.1℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.09(s,3H),3.36(d,J＝11.2Hz,1H),3.48(d,J＝11.2Hz,1H),6.68(d,J＝6.0Hz,1H),6.89-6.95(m,2H),7.05-7.09(m,1H),7.20-7.27(m,2H),7.40-7.42(m,1H),7.48-7.50(m,1H),9.32(brs,1H)；13C NMR(CDCl3,100MHz)δ:42.0,53.2,83.2,110.5,122.6,125.6,126.8,128.5,129.8,132.4,132.8,134.4,140.9,179.0；HRMS(ESI-TOF)m/z:Calcd.forC16H14BrNNaO2[M+Na]+:354.0106；Found:354.0105.
本实施例制备化合物3fa：淡黄色固体，熔点：138.2-139.8℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.09(s,3H),3.35(d,J＝13.5Hz,1H),3.47(d,J＝13.5Hz,1H),6.77(d,J＝7.2Hz,1H),6.89-6.97(m,2H),7.13-7.26(m,4H),7.42-7.44(m,1H),9.40(br s,1H)；13C NMR(CDCl3,100MHz)δ:39.4,53.2,83.3,110.4,122.6,125.5,125.9,126.2,128.3,129.1,129.8,132.5,132.7,135.3,140.5,141.0,179.0；HRMS(ESI-TOF)m/z:Calcd.for C16H14ClNNaO2[M+Na]+:310.0611；Found:310.0614.
本实施例制备化合物3ga：淡黄色固体，熔点：125.2-127.3℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.05(d,J＝12.8Hz,1H),3.08(s,3H),3.27(d,J＝12.8Hz,1H),6.83(d,J＝7.6Hz,1H),6.88(d,J＝8.4Hz,2H),7.02-7.08(m,4H),7.24-7.28(m,1H),8.93(br s,1H)；13C NMR(CDCl3,100MHz)δ:42.9,53.3,83.9,110.5,122.8,125.3,126.1,127.8,130.0,131.9,132.4,132.8,141.1,178.3；HRMS(ESI-TOF)m/z:Calcd.for C16H14ClNNaO2[M+Na]+:310.0611；Found:310.0610.
本实施例制备化合物3ha：淡黄色固体，熔点：135.7-138.2℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,500MHz)δ:3.07(d,J＝13.5Hz,1H),3.09(s,3H),3.31(d,J＝13.5Hz,1H),6.70-6.75(m,2H),6.83-6.85(m,2H),6.98-7.06(m,3H),7.24-7.27(m,1H),9.12(br s,1H)；13C NMR(CDCl3,125MHz)δ:43.2,53.3,83.8,110.5,110.6,113.7(d,JCF＝20.8Hz),117.4(d,JCF＝21.3Hz),122.7,125.3,126.0,126.3,126.4,128.9,129.0,130.0,136.5,136.6,141.1,141.2,162.1(d,JCF＝245.8Hz),178.5；HRMS(ESI-TOF)m/z:Calcd.for C16H14FNNaO2[M+Na]+:294.0906；Found:294.0908.
本实施例制备化合物3ia：淡黄色固体，熔点：130.4-133.3℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.00(s,3H),3.03(d,J＝12.8Hz,1H),3.21(d,J＝12.8Hz,1H),6.66(d,J＝8.4Hz,1H),6.87-6.92(m,3H),7.01-7.08(m,3H),7.13-7.19(m,1H),8.83(br s,1H)；13C NMR(CDCl3,100MHz)δ:43.6,53.5,84.3,111.4,125.6,127.0,127.8,128.2,128.3,129.8,130.5,133.4,139.6,178.2；HRMS(ESI-TOF)m/z:Calcd.forC16H14ClNNaO2[M+Na]+:310.0611；Found:310.0611.
本实施例制备化合物3ja：淡黄色固体，熔点：198.4-201.9℃；核磁共振和高分辨质谱测试结果如下：1H NMR(DMSO-d6,400MHz)δ:2.91(s,3H),3.00(d,J＝12.8Hz,1H),3.20(d,J＝12.8Hz,1H),6.66(s,1H),6.67-6.90(m,2H),7.03(d,J＝2.0Hz,1H),7.09-7.13(m,4H),10.5(br s,1H)；13C NMR(DMSO-d6,100MHz)δ:42.3,52.3,83.1,109.9,121.5,125.0,126.6,126.8,127.7,130.3,134.0,134.1,143.9,176.2；HRMS(ESI-TOF)m/z:Calcd.forC16H14ClNNaO2[M+Na]+:310.0611；Found:310.0611.
本实施例制备化合物3ab：淡黄色固体，熔点：112.0-113.8℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:1.14-1.18(m,3H),3.10-3.15(m,2H),3.22-3.26(m,1H),3.31(d,J＝12.8Hz,1H),6.78(d,J＝7.6Hz,1H),6.92-6.93(m,2H),6.94-7.10(m,5H),7.20-7.26(m,1H),9.01(br s,1H)；13CNMR(CDCl3,100MHz)δ:15.3,43.8,61.2,83.6,110.3,122.5,125.1,126.7,127.1,127.6,129.6,130.5,134.0,141.0,179.0；HRMS(ESI-TOF)m/z:Calcd.forC17H17NNaO2[M+Na]+:290.1157；Found:290.1154.
本实施例制备化合物3bb：淡黄色固体，熔点：151.2-153.1℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:1.12-1.16(m,3H),3.02-3.12(m,2H),3.19-3.26(m,2H),3.65(s,3H),6.56-6.58(m,2H),6.76-6.84(m,3H),7.01-7.06(m,2H),7.18-7.25(m,1H),8.93(br s,1H)；13C NMR(CDCl3,100MHz)δ:15.5,43.1,55.1,61.3,83.8,110.4,113.1,122.6,125.2,126.1,127.5,129.7,131.6,141.2,158.4,179.1；HRMS(ESI-TOF)m/z:Calcd.for C18H19NNaO3[M+Na]+:320.1263；Found:320.1263.
本实施例制备化合物3cb：淡黄色固体，熔点：138.8-141.9℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:1.07-1.10(m,3H),2.13(s,3H),2.99-3.07(m,2H),3.14-3.22(m,2H),6.69-6.79(m,5H),6.94-7.01(m,2H),7.12-7.18(m,1H),8.82(brs,1H)；13C NMR(CDCl3,100MHz)δ:15.3,21.0,43.4,61.1,83.6,110.2,122.5,125.1,127.3,128.3,129.6,130.4,130.8,136.1,141.0,178.9；HRMS(ESI-TOF)m/z:Calcd.forC18H19NNaO2[M+Na]+:304.1313；Found:304.1315.
本实施例制备化合物3db：淡黄色固体，熔点：142.1-144.6℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:1.15-1.18(m,3H),3.04(d,J＝13.2Hz,1H),3.11-3.15(m,1H),3.22-3.28(m,2H),6.78-6.84(m,3H),7.03-7.05(m,2H),7.18-7.27(m,3H),8.82(br s,1H)；13C NMR(CDCl3,100MHz)δ:15.3,43.2,61.3,83.2,110.4,120.9,122.7,125.1,126.8,129.8,130.7,132.3,133.0,140.8,178.6；HRMS(ESI-TOF)m/z:Calcd.for C17H16BrNNaO2[M+Na]+:368.0262；Found:368.0265.
本实施例制备化合物3eb：淡黄色固体，熔点：185.1-186.2℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:1.14-1.18(m,3H),3.07-3.11(m,1H),3.23-3.28(m,1H),3.32(d,J＝13.6Hz,1H),3.47(d,J＝13.6Hz,1H),6.65(d,J＝7.2Hz,1H),6.86-6.92(m,2H),7.05-7.07(m,1H),7.18-7.25(m,2H),7.38-7.40(m,1H),7.49-7.52(m,1H)；13C NMR(CDCl3,100MHz)δ:15.4,42.2,61.2,82.7,110.5,122.6,125.6,126.5,126.7,126.9,128.6,129.7,132.4,132.9,134.7,140.9,179.4；HRMS(ESI-TOF)m/z:Calcd.forC17H16BrNNaO2[M+Na]+:368.0262；Found:368.0262.
本实施例制备化合物3fb：淡黄色固体，熔点：207.1-209.2℃；核磁共振和高分辨质谱测试结果如下：1H NMR(DMSO-d6,400MHz)δ:1.01-1.05(m,3H),2.91-2.95(m,1H),3.05-3.08(m,1H),3.14(d,J＝12.8Hz,1H),3.32(d,J＝12.8Hz,1H),6.72(d,J＝7.8Hz,1H),6.80-6.87(m,2H),7.14-7.28(m,5H),10.5(br s,1H)；13C NMR(DMSO-d6,100MHz)δ:15.3,40.1,60.0,82.0,109.8,121.5,124.8,126.5,128.6,129.0,129.7,132.2,132.5,142.0,176.7；HRMS(ESI-TOF)m/z:Calcd.forC17H16ClNNaO2[M+Na]+:324.0767；Found:324.0769.
本实施例制备化合物3gb：淡黄色固体，熔点：154.1-156.2℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:1.14-1.18(m,3H),3.06(d,J＝12.8Hz,1H),3.11-3.15(m,1H),3.21-3.25(m,1H),3.28(d,J＝12.8Hz,1H),6.81(d,J＝8.0Hz,1H),6.88(d,J＝8.4Hz,2H),7.02-7.05(m,4H),7.22-7.27(m,1H),9.04(br s,1H)；13C NMR(CDCl3,100MHz)δ:15.3,43.1,61.3,83.3,110.4,122.7,125.1,126.9,127.7,129.8,131.9,132.5,132.7,140.9,178.7；HRMS(ESI-TOF)m/z:Calcd.for C17H16ClNNaO2[M+Na]+:324.0767；Found:324.0766.
本实施例制备化合物3hb：淡黄色固体，熔点：118.3-119.8℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,500MHz)δ:1.16-1.19(m,3H),3.08(d,J＝13.0Hz,1H),3.12-3.15(m,1H),3.24-3.27(m,1H),3.31(d,J＝13.0Hz,1H),6.69-6.75(m,2H),6.80-6.83(m,2H),7.00-7.05(m,3H),7.22-7.26(m,1H),9.10(brs,1H)；13C NMR(CDCl3,125MHz)δ:15.3,43.4,61.2,83.2,110.4,110.5,113.6,113.7,117.4(d,JCF＝21.3Hz),122.7,125.1,126.3,126.4,126.8,128.9(d,JCF＝8.8Hz),129.8,136.6(d,JCF＝7.5Hz),140.9,162.1(d,JCF＝243.8Hz),178.7；HRMS(ESI-TOF)m/z:Calcd.for C17H16FNNaO2[M+Na]+:308.1063；Found:308.1067.
本实施例制备化合物3ac：淡黄色固体，熔点：146.1-148.3℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.84-0.88(m,3H),1.54-1.60(m,2H),2.95-3.01(m,1H),3.08(d,J＝12.8Hz,1H),3.15-3.20(m,1H),3.33(d,J＝12.8Hz,1H),6.78(d,J＝7.6Hz,1H),6.96-7.13(m,7H),7.19-7.26(m,1H),8.90(br s,1H)；13C NMR(CDCl3,100MHz)δ:10.5,23.1,43.8,67.2,83.4,110.2,122.5,125.3,126.7,127.2,127.6,129.6,130.7,134.1,140.9,178.9；HRMS(ESI-TOF)m/z:Calcd.for C18H19NNaO2[M+Na]+:304.1313；Found:304.1315.
本实施例制备化合物3bc：淡黄色固体，熔点：145.5-146.9℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.81-0.85(m,3H),1.52-1.56(m,2H),2.94-3.02(m,2H),3.12-3.15(m,1H),3.25(d,J＝12.8Hz,1H),3.66(s,3H),6.57-6.60(m,2H),6.78(d,J＝7.6Hz,1H),6.84-6.87(m,2H),6.97-7.00(m,2H),7.19-7.25(m,1H),8.99(brs,1H)；13C NMR(CDCl3,100MHz)δ:10.7,23.2,43.0,55.1,67.3,83.6,110.4,113.1,122.6,125.4,126.2,127.5,129.7,131.7,141.2,158.4,179.3；HRMS(ESI-TOF)m/z:Calcd.forC19H21NNaO3[M+Na]+: 334.1419；Found:334.1415.
本实施例制备化合物3cc：淡黄色固体，熔点：75.1-76.8℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.76-0.80(m,3H),1.46-1.53(m,2H),2.15(s,3H),2.89-2.93(m,1H),2.98(d,J＝12.8Hz,1H),3.08-3.11(m,1H),3.21(d,J＝12.8Hz,1H),6.68(d,J＝7.6Hz,1H),6.76-6.82(m,4H),6.92-6.97(m,2H),7.12-7.19(m,1H),8.41(br s,1H)；13C NMR(CDCl3,100MHz)δ:10.5,21.0,23.1,43.4,67.2,83.3,110.1,122.4,125.3,127.4,128.3,129.5,130.5,130.9,136.1,140.9,178.7；HRMS(ESI-TOF)m/z:Calcd.for C19H21NNaO2[M+Na]+:318.1470；Found:318.1472.
本实施例制备化合物3dc：淡黄色固体，熔点：143.3-144.8℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.84-0.87(m,3H),1.53-1.59(m,2H),2.95-3.02(m,2H),3.14-3.19(m,1H),3.27(d,J＝12.8Hz,1H),6.81-6.86(m,3H),6.94-6.96(m,1H),7.01-7.04(m,1H),7.20-7.24(m,3H),8.88(brs,1H)；13C NMR(CDCl3,100MHz)δ:10.5,23.0,43.1,67.2,83.0,110.4,120.9,122.6,125.2,126.9,129.8,130.7,132.4,133.2,140.8,178.7；HRMS(ESI-TOF)m/z:Calcd.for C18H18BrNNaO2[M+Na]+:382.0419；Found:382.0417.
本实施例制备化合物3ec：淡黄色固体，熔点：153.1-154.9℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.85-0.88(m,3H),1.54-1.62(m,2H),2.95(d,J＝6.0Hz,1H),3.21(d,J＝6.4Hz,1H),3.32(d,J＝11.2Hz,1H),3.48(d,J＝11.2Hz,1H),6.59(d,J＝6.0Hz,1H),6.89-6.92(m,2H),7.07-7.09(m,1H),7.21-7.26(m,2H),7.41(d,J＝6.4Hz,1H),7.56(d,J＝6.0Hz,1H),9.22(br s,1H)；13C NMR(CDCl3,100MHz)δ:10.6,23.1,42.1,67.0,82.3,110.3,122.5,125.5,126.5,126.6,126.7,128.4,129.6,132.3,133.0,134.7,140.7,179.2；HRMS(ESI-TOF)m/z:Calcd.for C18H18BrNNaO2[M+Na]+:382.0419；Found:382.0421.
本实施例制备化合物3fc：淡黄色固体，熔点：160.3-161.9℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.85-0.88(m,3H),1.56-1.62(m,2H),2.94-2.98(m,1H),3.18-3.22(m,1H),3.33(d,J＝13.6Hz,1H), 3.46(d,J＝13.6Hz,1H),6.69(d,J＝7.2Hz,1H),6.86-6.94(m,2H),7.13-7.26(m,4H),7.51(d,J＝4.0Hz,1H),9.15(br s,1H)；13C NMR(CDCl3,100MHz)δ:10.6,23.1,39.6,67.1,82.4,110.2,122.5,125.4,126.0,126.7,128.2,129.0,129.6,132.8,135.3,140.8,179.2；HRMS(ESI-TOF)m/z:Calcd.forC18H18ClNNaO2[M+Na]+:338.0924；Found:338.0924.
本实施例制备化合物3gc：淡黄色固体，熔点：158.1-161.2℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.84-0.87(m,3H),1.53-1.60(m,2H),2.96-3.00(m,1H),3.03(d,J＝12.8Hz,1H),3.14-3.18(m,1H),3.29(d,J＝12.8Hz,1H),6.81(d,J＝7.6Hz,1H),6.89-6.97(m,3H),7.01-7.07(m,3H),7.22-7.26(m,1H),8.90(br s,1H)；13CNMR(CDCl3,100MHz)δ:10.5,23.0,43.1,67.3,83.0,110.3,122.6,125.2,126.9,127.7,129.8,132.0,132.7,140.8,178.7；HRMS(ESI-TOF)m/z:Calcd.for C18H18ClNNaO2[M+Na]+:338.0924；Found:338.0927.
本实施例制备化合物3dd：淡黄色固体，熔点：148.1-150.1℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,500MHz)δ:1.01(d,J＝6.5Hz,3H),1.10(d,J＝6.0Hz,3H),2.97(d,J＝13.0Hz,1H),3.23(d,J＝13.0Hz,1H),6.78-6.83(m,3H),6.98-7.02(m,2H),7.19-7.27(m,3H),8.57(br s,1H)；13C NMR(CDCl3,125MHz)δ:23.1,24.1,43.8,69.5,82.7,110.3,120.9,122.4,125.6,127.3,129.8,130.6,132.4,133.2,140.6,179.3；HRMS(ESI-TOF)m/z:Calcd.forC18H18BrNNaO2[M+Na]+:382.0419；Found:382.0419.
本实施例制备化合物3ed：淡黄色固体，熔点：182.0-183.3℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.99(d,J＝6.0Hz,3H),1.10(d,J＝6.0Hz,3H),3.24(d,J＝14.0Hz,1H),3.40-3.44(m,2H),6.53(d,J＝7.2Hz,1H),6.84-6.89(m,2H),7.03-7.08(m,1H),7.18-7.25(m,2H),7.37-7.41(m,1H),7.55-7.57(m,1H),9.16(br s,1H)；13C NMR(CDCl3,100MHz)δ:23.2,24.0,42.7,69.3,82.1,110.5,122.4,126.1,126.7,126.8,126.9,128.5,129.7,132.3,133.1,134.9,140.6,180.4；HRMS(ESI-TOF)m/z:Calcd.for C18H18BrNNaO2[M+Na]+:382.0419；Found:382.0422.
本实施例制备化合物3fd：淡黄色固体，熔点：197.2-198.7℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:1.01(d,J＝6.0Hz,3H),1.12(d,J＝6.0Hz,3H),3.27(d,J＝13.6Hz,1H),3.40-3.45(m,2H),6.66(d,J＝7.2Hz,1H),6.87-6.92(m,2H),7.12-7.26(m,4H),7.49-7.52(m,1H),9.16(br s,1H)；13C NMR(CDCl3,100MHz)δ:23.1,24.0,40.1,69.2,82.1,110.3,122.2,125.9,126.0,127.0,128.1,128.9,129.6,132.9,135.4,140.5,180.1；HRMS(ESI-TOF)m/z:Calcd.for C18H18ClNNaO2[M+Na]+:338.0924；Found:338.0925.
本实施例制备化合物3gd：淡黄色固体，熔点：198.2-201.3℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:1.01(d,J＝6.4Hz,3H),1.08(d,J＝6.0Hz,3H),2.98(d,J＝12.8Hz,1H),3.25(d,J＝12.8Hz,1H),3.38-3.45(m,1H),6.81(d,J＝7.6Hz,1H),6.86-6.89(m,2H),6.97-7.04(m,4H),7.22-7.27(m,1H),8.97(br s,1H)；13CNMR(CDCl3,100MHz)δ:23.1,24.1,43.7,69.5,82.8,110.4,122.4,125.6,127.3,127.7,129.8,132.0,132.6,132.7,140.6,179.6；HRMS(ESI-TOF)m/z:Calcd.for C18H18ClNNaO2[M+Na]+:338.0924；Found:338.0926.
本实施例制备化合物3ae：淡黄色固体，熔点：125.5-126.7℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.82-0.85(m,3H),1.28-1.36(m,2H),1.49-1.54(m,2H),3.01-3.09(m,2H),3.16-3.20(m,1H),3.32(d,J＝12.8Hz,1H),6.78-6.81(m,1H),6.95-7.11(m,7H),7.19-7.26(m,1H),9.01(br s,1H)；13C NMR(CDCl3,100MHz)δ:13.8,19.1,31.8,43.8,65.3,83.4,110.3,122.4,125.2,126.7,127.2,127.5,129.6,130.6,134.1,141.0,179.1；HRMS(ESI-TOF)m/z:Calcd.for C19H21NNaO2[M+Na]+:318.1470；Found:318.1473.
本实施例制备化合物3be：淡黄色固体，熔点：139.5-141.7℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.81-0.85(m,3H),1.28-1.34(m,2H),1.48-1.52(m,2H),6.59(d,J＝8.4Hz,2H),6.80(d,J＝7.6Hz,1H),6.87(d,J＝8.8Hz,2H),6.97-7.04(m,2H),7.20-7.24(m,1H),9.08(br s,1H)；13C NMR(CDCl3,100MHz)δ:13.8,19.1,31.8,42.9,54.9,65.2,83.5,110.3,112.9,122.4,125.2,126.1,127.3,129.5,131.5,141.0,158.2,179.1；HRMS(ESI-TOF)m/z:Calcd.for C20H23NNaO3[M+Na]+:348.1576；Found:348.1576.
本实施例制备化合物3ce：淡黄色固体，熔点：105.1-107.7℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.74-0.78(m,3H),1.22-1.25(m,2H),1.43-1.48(m,2H),2.13(s,3H),2.93-2.98(m,2H),3.10-3.13(m,1H),3.20(d,J＝13.2Hz,1H),6.71(d,J＝8.0Hz,1H),6.75-6.81(m,4H),6.90-6.94(m,2H),7.12-7.18(m,1H),8.87(brs,1H)；13C NMR(CDCl3,100MHz)δ:13.8,19.1,21.0,31.9,43.3,65.2,83.4,110.2,122.4,125.2,127.3,128.2,129.5,130.5,130.9,136.1,141.0,179.0；HRMS(ESI-TOF)m/z:Calcd.for C20H23NNaO2[M+Na]+:332.1626；Found:332.1629.
本实施例制备化合物3de：淡黄色固体，熔点：136.0-138.1℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.82-0.85(m,3H),1.30-1.35(m,2H),1.48-1.54(m,2H),2.99-3.03(m,2H),3.17-3.19(m,1H),3.27(d,J＝13.0Hz,1H),6.80-6.86(m,3H),6.94-6.96(m,1H),7.01-7.04(m,1H),7.20-7.27(m,3H),8.93(br s,1H)；13C NMR(CDCl3,100MHz)δ:13.8,19.1,31.8,43.1,65.3,83.0,110.4,120.9,122.6,125.2,126.9,129.8,130.7,132.4,133.2,140.8,178.7；HRMS(ESI-TOF)m/z:Calcd.for C19H20BrNNaO2[M+Na]+:396.0575；Found:396.0578.
本实施例制备化合物3ee：淡黄色固体，熔点：98.9-99.3℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.82-0.85(m,3H),1.25-1.36(m,2H),1.45-1.51(m,2H),3.00-3.01(m,1H),3.22-3.24(m,1H),3.32(d,J＝11.2Hz,1H),3.48(d,J＝11.2Hz,1H),6.59(d,J＝6.0Hz,1H),6.89-6.92(m,2H),7.07-7.08(m,1H),7.20-7.25(m,2H),7.40-7.42(m,1H),7.55(d,J＝6.0Hz,1H),9.55(br s,1H)；13C NMR(CDCl3,100MHz)δ:13.8,19.2,31.8,42.1,65.1,82.4,110.4,122.4,125.4,126.5,126.6,126.7,128.4,129.5,132.3,132.9,134.7,140.8,179.4；HRMS(ESI-TOF)m/z:Calcd.for C19H20BrNNaO2[M+Na]+:396.0575；Found:396.0575.
本实施例制备化合物3fe：淡黄色固体，熔点：142.1-144.0℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.82-0.86(m,3H),1.33-1.38(m,2H),1.49-1.57(m,2H),2.97-3.03(m,1H),3.20-3.25(m,1H),3.32(d,J＝13.6Hz,1H),3.46(d,J＝13.6Hz,1H),6.69(d,J＝7.6Hz,1H),6.87-6.94(m, 2H),7.13-7.26(m,4H),7.47-7.50(m,1H),9.29(br s,1H)；13C NMR(CDCl3,100MHz)δ:13.8,19.2,31.8,39.6,65.1,82.5,110.3,122.5,125.4,126.0,126.7,128.2,129.0,129.6,132.8,132.9,135.3,140.7,179.2；HRMS(ESI-TOF)m/z:Calcd.forC19H20ClNNaO2[M+Na]+:352.1080；Found:352.1082.
本实施例制备化合物3ge：淡黄色固体，熔点：142.1-144.3℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:0.81-0.85(m,3H),1.30-1.34(m,2H),1.50-1.54(m,2H),3.00-3.05(m,2H),3.16-3.21(m,1H),3.28(d,J＝12.8Hz,1H),6.80-6.83(m,1H),6.89-6.96(m,3H),7.01-7.06(m,3H),7.21-7.27(m,1H),9.09(br s,1H)；13C NMR(CDCl3,100MHz)δ:13.7,19.1,31.8,43.1,65.3,83.1,110.4,122.6,125.1,126.9,127.7,129.7,132.0,132.7,140.9,178.8；HRMS(ESI-TOF)m/z:Calcd.for C19H20ClNNaO2[M+Na]+:352.1080；Found:352.1083.
本实施例制备化合物3he：淡黄色固体，熔点：129.0-131.1℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,500MHz)δ:0.82-0.86(m,3H),1.26-1.35(m,2H),1.45-1.57(m,2H),3.02-3.05(m,2H),3.19-3.22(m,1H),3.32(d,J＝13.5Hz,1H),6.72-6.76(m,2H),6.80-6.84(m,2H),6.91-6.95(m,1H),7.01-7.05(m,2H),7.22-7.26(m,1H),9.18(brs,1H)；13C NMR(CDCl3,125MHz)δ:13.7,19.1,31.8,43.4,65.3,83.0,110.4,113.6(d,JCF＝21.1Hz),117.4(d,JCF＝21.2Hz),122.6,125.1,126.4,126.9,128.8,128.9,129.8,136.7,136.8,140.9,162.1(d,JCF＝243.8Hz),178.9；HRMS(ESI-TOF)m/z:Calcd.for C19H20FNNaO2[M+Na]+:336.1376；Found:336.1377.
本实施例制备化合物3af：淡黄色固体，熔点：168.8-170.3℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.18(d,J＝12.8Hz,1H),3.41(d,J＝12.8Hz,1H),4.12(d,J＝8.2Hz,1H),4.25(d,J＝12.8Hz,1H),6.80(d,J＝8.0Hz,1H),6.97-7.10(m,7H),7.21-7.29(m,6H),8.97(br s,1H)；13C NMR(CDCl3,100MHz)δ:43.8,67.8,83.8,110.4,122.6,125.4,126.8,127.6,127.7,127.8,128.2,129.9,130.7,133.9,137.5,141.1,178.4；HRMS(ESI-TOF)m/z:Calcd.forC22H19NNaO2[M+Na]+:352.1313；Found:352.1313.
本实施例制备化合物3bf：淡黄色固体，熔点：218.1-219.8℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.12(d,J＝13.2Hz,1H),3.34(d,J＝13.2Hz,1H),3.64(s,3H),4.11(d,J＝10.8Hz,1H),4.23(d,J＝10.4Hz,1H),6.58-6.61(m,2H),6.79-6.81(m,1H),6.87-6.89(m,2H),7.05-7.10(m,2H),7.22-7.29(m,6H),8.88(br s,1H)；13C NMR(CDCl3,100MHz)δ:43.0,55.1,68.0,84.0,110.6,113.2,122.8,125.5,126.0,127.1,127.8,128.0,128.3,130.0,131.8,137.7,141.2,158.5,178.7；HRMS(ESI-TOF)m/z:Calcd.for C23H21NNaO3[M+Na]+:382.1419；Found:382.1421.
本实施例制备化合物3cf：淡黄色固体，熔点：132.2-134.3℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:2.10(s,3H),3.06(d,J＝13.2Hz,1H),3.28(d,J＝12.8Hz,1H),4.03(d,J＝10.4Hz,1H),4.16(d,J＝10.8Hz,1H),6.72(d,J＝8.0Hz,1H),6.78(s,4H),6.96-7.02(m,2H),7.14-7.20(m,6H),8.93(br s,1H)；13C NMR(CDCl3,100MHz)δ:21.0,43.3,67.8,83.8,110.4,122.6,125.3,126.9,127.6,127.8,128.2,128.4,129.8,130.5,130.7,136.2,137.6,141.1,178.5；HRMS(ESI-TOF)m/z:Calcd.for C23H21NNaO2[M+Na]+:366.1470；Found:366.1474.
本实施例制备化合物3df：淡黄色固体，熔点：201.2-203.2℃；核磁共振和高分辨质谱测试结果如下：1H NMR(DMSO-d6,400MHz)δ:3.08(d,J＝10.0Hz,1H),3.27(d,J＝10.0Hz,1H),3.99(d,J＝8.4Hz,1H),4.12(d,J＝8.4Hz,1H),6.71(d,J＝6.0Hz,1H),6.86(d,J＝6.4Hz,1H),7.19-7.22(m,1H),7.26-7.31(m,9H)；13C NMR(DMSO-d6,100MHz)δ:41.4,66.1,82.3,109.5,119.5,121.4,124.5,125.6,127.0,127.1,127.7,129.5,130.0,132.0,133.2,137.2,141.8,175.6；HRMS(ESI-TOF)m/z:Calcd.for C22H18BrNNaO2[M+Na]+:430.0419；Found:430.0423.
本实施例制备化合物3ef：淡黄色固体，熔点：158.8-160.1℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.42(d,J＝14.0Hz,1H),3.58(d,J＝14.0Hz,1H),4.12(d,J＝10.8Hz,1H),4.30(d,J＝10.8Hz,1H),6.70(d,J＝7.6Hz,1H),6.91-6.95(m,2H),7.07-7.09(m,1H),7.21-7.30(m,7H),7.42(d,J＝8.1Hz,1H),7.56(d,J＝8.0Hz,1H),9.35(br s,1H)；13C NMR(CDCl3,100MHz)δ:42.2,67.8,82.9,110.7,122.8,125.8,126.3,126.6,127.0,127.7,127.8,128.3,128.7,130.0,132.5,133.1,134.6,137.8,141.0,179.0；HRMS(ESI-TOF)m/z:Calcd.for C22H18BrNNaO2[M+Na]+:430.0419；Found:430.0418.
本实施例制备化合物3ff：淡黄色固体，熔点：145.3-147.2℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.42(d,J＝14.0Hz,1H),3.56(d,J＝13.6Hz,1H),4.12(d,J＝10.8Hz,1H),4.29(d,J＝10.8Hz,1H),6.80(d,J＝7.2Hz,1H),6.89-6.96(m,2H),7.12-7.15(m,2H),7.20-7.28(m,7H),7.48-7.50(m,1H),9.34(br s,1H)；13C NMR(CDCl3,100MHz)δ:39.6,67.7,82.9,110.5,122.6,125.5,126.1,126.3,127.6,128.2,128.3,129.1,129.9,132.6,132.9,135.3,137.6,140.8,178.7；HRMS(ESI-TOF)m/z:Calcd.for C22H18ClNNaO2[M+Na]+:386.0924；Found:386.0925.
本实施例制备化合物3gf：淡黄色固体，熔点：110.3-112.8℃；核磁共振和高分辨质谱测试结果如下：1H NMR(DMSO-d6,400MHz)δ:3.09(d,J＝12.8Hz,1H),3.29(d,J＝12.8Hz,1H),3.99(d,J＝10.8Hz,1H),4.13(d,J＝10.8Hz,1H),6.71(d,J＝8.0Hz,1H),6.92(d,J＝8.4Hz,2H),7.00-7.03(m,1H),7.15-7.30(m,9H),10.5(br s,1H)；13C NMR(DMSO-d6,100MHz)δ:41.4,66.1,82.4,109.5,121.4,124.5,125.7,127.0,127.1,127.7,129.5,131.0,131.6,132.9,137.2,141.8,175.6；HRMS(ESI-TOF)m/z:Calcd.for C22H18ClNNaO2[M+Na]+:386.0924；Found:386.0924.
本实施例制备化合物3hf：淡黄色固体，熔点：153.2-155.1℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,500MHz)δ:3.16(d,J＝10.4Hz,1H),3.39(d,J＝13.4Hz,1H),4.13(d,J＝11.0Hz,1H),4.27(d,J＝10.5Hz,1H),6.72-6.74(m,1H),6.76-6.78(m,1H),6.81-6.84(m,2H),7.04-7.06(m,3H),7.23-7.29(m,6H)；13C NMR(CDCl3,125MHz)δ:43.4,67.9,83.4,110.5,113.7(d,JCF＝20.1Hz),117.4(d,JCF＝21.3Hz),122.8,125.3,126.5,127.7,127.8,128.3,129.0,129.1,130.1,136.5,137.4,141.0,162.1(d,JCF＝243.8Hz),178.2；HRMS(ESI-TOF)m/z:Calcd.for C22H18FNNaO2[M+Na]+:370.1219；Found:370.1221.
本实施例制备化合物3if：淡黄色固体，熔点：217.3-220.5℃；核磁共振和高分辨质谱测试结果如下：1H NMR(DMSO-d6,400MHz)δ:3.09(d,J＝12.4H,1H),3.33(d,J＝12.8Hz,1H),4.03(d,J＝10.8Hz,1H),4.16(d,J＝10.8Hz,1H),6.68(d, J＝8.8Hz,1H),6.92-6.95(m,2H),7.11-7.13(m,3H),7.22-7.32(m,7H),10.6(br s,1H)；13C NMR(DMSO-d6,100MHz)δ:42.4,66.8,83.2,111.3,125.2,125.9,126.8,127.5,127.6,127.7,128.2,128.5,129.7,130.3,133.9,137.6,141.2,176.0；HRMS(ESI-TOF)m/z:Calcd.for C22H18ClNNaO2[M+Na]+:386.0924；Found:386.0926.
本实施例制备化合物3jf：淡黄色固体，熔点：165.1-168.5℃；核磁共振和高分辨质谱测试结果如下：1H NMR(CDCl3,400MHz)δ:3.04(d,J＝13.2Hz,1H),3.31(d,J＝13.2Hz,1H),4.01(d,J＝10.8Hz,1H),4.16(d,J＝10.8Hz,1H),6.75-6.76(m,1H),6.84-6.94(m,4H),7.00-7.06(m,3H),7.16-7.23(m,5H),9.04(brs,1H)；13C NMR(CDCl3,100MHz)δ:43.6,67.9,83.4,111.2,122.7,125.1,126.4,127.0,127.8,128.3,130.7,133.6,135.5,137.2,142.1,178.5；HRMS(ESI-TOF)m/z:Calcd.for C22H18ClNNaO2[M+Na]+:386.0924；Found:386.0925.
本发明的实施例2：化合物3aa:在圆底烧瓶中，依次加入3-氯季碳氧化吲哚1a(0.4mmol)，4.0mL甲醇2a，20mol％Et3N(8.1mg,0.08mmol)，充分搅拌，室温反应8小时。减压蒸馏除掉溶剂，残留油状物硅胶柱层析(300-400目)分离(石油醚：乙酸乙酯＝8：1)，得到淡黄色固体。产率：89％。
采用本实施例2制备，投料比与化合物3aa相同，可分别得到化合物3ba(产率91％)，化合物3ca(产率88％)，化合物3da(产率89％)，化合物3ea(产率88％)，化合物3fa(产率87％)，化合物3ga(产率92％)，化合物3ha(产率88％)，化合物3ia(产率96％)，化合物3ja(产率87％)，化合物3ab(产率86％)，化合物3bb(产率86％)，化合物3cb(产率88％)，化合物3db(产率86％)，化合物3eb(产率84％)，化合物3fb(产率85％)，化合物3gb(产率83％)，化合物3hb(产率87％)，化合物3ac(产率80％)，化合物3bc(产率85％)，化合物3cc(产率82％)，化合物3dc(产率86％)，化合物3ec(产率80％)，化合物3fc(产率82％)，化合物3gc(产率78％)，化合物3dd(产率77％)，化合物3ed(产率75％)，化合物3fd(产率74％)，化合物3gd(产率70％)，化合物3ae(产率79％)，化合物3be(产率75％)，化合物3ce(产率73％),化合物3de(产率73％)；化合物3ee(产率72％)，化合物3fe(产率73％)，化合物3ge(产率71％)，化合物3he(产率75％)，化合物3af(产率78％)，化合物3bf(产率73％),化合物3cf(产率78％)；化合物3df(产率82％)，化合物3ef(产率83％)，化合物3ff(产率82％)，化合物3gf(产率85％)，化合物3hf(产率83％)，化合物3if(产率85％),化合物3jf(产率88％)。

Claims (7)

1.一种3-烷氧基季碳氧化吲哚，其特征在于：该化合物具有如下通式(I)的结构：
式中，R1为苯环上不同取代的苄基；R2为氢或卤素；R3为烷基。
2.一种如权利要求1所述的3-烷氧基季碳氧化吲哚的制备方法，其特征在于：将3-氯季碳氧化吲哚在醇类溶剂中,加入无机碱或者有机碱,进行3-烷氧基化反应，获得3-烷氧基季碳氧化吲哚。
3.根据权利要求2所述的3-烷氧基季碳氧化吲哚的制备方法，其特征在于：所述的无机碱包括碳酸钠、碳酸钾、碳酸氢钠、碳酸氢钾、磷酸钾或磷酸氢钾。
4.根据权利要求2所述的3-烷氧基季碳氧化吲哚的制备方法，其特征在于：所述的有机碱为DBU、DMAP、Et3N或金鸡纳碱。
5.根据权利要求2所述的3-烷氧基季碳氧化吲哚的制备方法，其特征在于：所述的碱性催化剂的加入量为3-氯季碳氧化吲哚摩尔量的1-100％。
6.根据权利要求2所述的3-烷氧基季碳氧化吲哚的制备方法，其特征在于：所述的醇类溶剂为甲醇、乙醇、丙醇、异丙醇、正丁醇或苄醇。
7.根据权利要求2所述的3-烷氧基季碳氧化吲哚的制备方法，其特征在于：反应温度为25-100℃，反应时间为3-10小时。
CN201710131094.XA 2017-03-07 2017-03-07 3‑烷氧基季碳氧化吲哚及其制备方法 Pending CN106928122A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710131094.XA CN106928122A (zh) 2017-03-07 2017-03-07 3‑烷氧基季碳氧化吲哚及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710131094.XA CN106928122A (zh) 2017-03-07 2017-03-07 3‑烷氧基季碳氧化吲哚及其制备方法

Publications (1)

Publication Number Publication Date
CN106928122A true CN106928122A (zh) 2017-07-07

Family

ID=59424357

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710131094.XA Pending CN106928122A (zh) 2017-03-07 2017-03-07 3‑烷氧基季碳氧化吲哚及其制备方法

Country Status (1)

Country Link
CN (1) CN106928122A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108610277A (zh) * 2018-03-20 2018-10-02 贵州大学 3-叔胺四取代氧化吲哚化合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1157822A (zh) * 1995-12-19 1997-08-27 利利工业公司 药物化合物
CN101516366A (zh) * 2006-09-21 2009-08-26 霍夫曼-拉罗奇有限公司 作为抗癌剂的羟吲哚衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1157822A (zh) * 1995-12-19 1997-08-27 利利工业公司 药物化合物
CN101516366A (zh) * 2006-09-21 2009-08-26 霍夫曼-拉罗奇有限公司 作为抗癌剂的羟吲哚衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
尹冬冬主编: "《有机化学（上册）》", 30 April 2003, 高等教育出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108610277A (zh) * 2018-03-20 2018-10-02 贵州大学 3-叔胺四取代氧化吲哚化合物及其制备方法

Similar Documents

Publication Publication Date Title
Vijender et al. Amberlist-15 as heterogeneous reusable catalyst for regioselective ring opening of epoxides with amines under mild conditions
Lu et al. An odorless, one-pot synthesis of nitroaryl thioethers via SN Ar reactions through the in situ generation of S-alkylisothiouronium salts
CN107473982A (zh) 端位取代高烯丙基胺衍生物及其制备方法和用途
CN101146812A (zh) 光学活性铵盐化合物、其制造中间体和制造方法
CN106928122A (zh) 3‑烷氧基季碳氧化吲哚及其制备方法
CN110272366B (zh) 二芳基硒化物的合成方法
EP3207018A1 (en) Process for the preparation of 1-(3,5-dichloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone
ES2330479T3 (es) Procedimiento para la preparacion de duloxetina.
JP2007238540A (ja) 光学活性アルコール化合物の製法
JP6952974B2 (ja) アミド化合物の製造方法
CN103804273B (zh) 氧化吲哚与茚三酮双季碳拼接衍生物及其制备方法
CN110240572B (zh) 一种反式-1,1-环丙烷二羧酸酯的合成方法
JP5046213B2 (ja) 光学活性アルコール化合物の製法
CN113773294B (zh) 黄酮、异黄酮类化合物的制备方法及其应用
CN110590621A (zh) 一种铜催化端炔合成1,2-双(芳基磺酰基)乙烯衍生物的方法
JP3738225B2 (ja) 新規キラル銅触媒とそれを用いたｎ−アシル化アミノ酸誘導体の製造方法
JP4540197B2 (ja) （ｅ）−３−メチル−２−シクロペンタデセノンの製造法
CN113754613B (zh) 一种4-烯醇的苯硫基环醚化方法
CN102432487B (zh) 催化氨基乙酰化的方法
JP2010270092A (ja) アセチル化合物、該アセチル化合物の製造方法、および該アセチル化合物を使用したナフトール化合物の製造方法
Shivarkar et al. Tandem synthesis of β-amino alcohols from aniline, dialkyl carbonate, and ethylene glycol
CN100560561C (zh) 光学纯 α—二氟甲基胺和高立体选择性制备的方法
CN106478491B (zh) 3-氨甲基季碳氧化吲哚拼接3-五元碳环螺环氧化吲哚类化合物及其制备方法及应用
WO2013038931A1 (ja) 2-オキソ-2H-シクロヘプタ[b]フラン類縁体の製造方法
CN118388325A (zh) 一种1-萘酚类化合物的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170707